Le Lézard
Classified in: Health
Subject: CCA

Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2019 Results Presentation and Webcast


OSLO, Norway, Aug. 16, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that it will report its results for the second quarter and first half 2019 on Thursday, 22 August 2019.

A presentation by Nordic Nanovector's senior management team will take place at 8:30am CEST at:

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: AKER

The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investors & Media

The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2019 from 7:00am CEST the same day.

For further information, please contact: 

IR enquiries

Malene Brondberg
VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com  

Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedewerogerson.com  

About Nordic Nanovector: 

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act. 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--invitation-to-second-quarter-and-first-half-2019-results-presentation-and-web,c2882117

SOURCE Nordic Nanovector


These press releases may also interest you

at 19:40
MemoryCare.com, a comprehensive resource for caregivers and older adults living with memory impairment, has announced the Best Memory Care Facilities in Tulsa, Oklahoma. The guide identifies 4 memory care communities based on location, access to...

at 19:30
Below are experts from the ProfNet network who are available to discuss timely issues in your coverage area.   You can also submit a query to the hundreds of thousands of experts in our network ? it's easy and free. Just...

at 19:30
MemoryCare.com, a comprehensive resource for caregivers and older adults living with memory impairment, has announced the Best Memory Care Facilities in Amarillo, Texas. The guide identifies 5 memory care communities based on location, access to...

at 19:20
MemoryCare.com, a comprehensive resource for caregivers and older adults living with memory impairment, has announced the Best Memory Care Facilities in Medford, Oregon. The guide identifies 3 memory care communities based on location, access to...

at 19:15
Ronald C. Green, shareholder in the Houston office of global law firm Greenberg Traurig, LLP, has been appointed to The University of Texas Health Science Center at Houston (UTHealth) Development Board. The UTHealth Development Board consists of over...

at 18:58
Biological products play an increasingly central role in modern medicine, offering treatments for many serious illnesses. Commonly referred to as biologics, these medicines are generally made from natural or living sources, like animal and plant...



News published on 16 august 2019 at 02:14 and distributed by: